Goldman Joins JPMorgan in Ditching Sell Teva Call as Stock Jumps

Analysts at JPMorgan Chase & Co., Morgan Stanley and Goldman Sachs Group Inc. are abandoning their sell ratings on Teva Pharmaceutical Industries Ltd. as the stock posts its best quarterly rally since 2005.

All three banks raised their recommendations on Teva, the world’s biggest maker of generic drugs, to neutral from sell in the past two weeks as the stock soared to a three-year high in New York trading. The analysts said the company is making progress in its push to maintain market share of its best-selling drug Copaxone while a boom in mergers and acquisitions in the industry yields deals of as much as $21 billion.